Synthetic Biologics, Inc. (SYN): Price and Financial Metrics
GET POWR RATINGS... FREE!
SYN Stock Price Chart Interactive Chart >
SYN Price/Volume Stats
| Current price | $1.02 | 52-week high | $4.56 |
| Prev. close | $1.01 | 52-week low | $0.97 |
| Day low | $0.97 | Volume | 57,700 |
| Day high | $1.02 | Avg. volume | 197,338 |
| 50-day MA | $1.32 | Dividend yield | N/A |
| 200-day MA | $2.15 | Market Cap | 16.16M |
Synthetic Biologics, Inc. (SYN) Company Bio
Synthetic Biologics, Inc. is a clinical stage company developing therapeutics which protect microbiomes and target pathogen-specific diseases. The Company develops drugs that are designed to reduce the impact of methane-producing organisms to help treat the cause of IBS-C and designed to protect microbiomes and prevent CDI during IV antibiotic use.
Latest SYN News From Around the Web
Below are the latest news stories about SYNTHETIC BIOLOGICS INC that investors may wish to consider to help them evaluate SYN as an investment opportunity.
Synthetic Biologics Rebrands as Theriva BiologicsRebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administrationROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and branding elements were introduced to better reflect Theriva’s position as a clinical-stage pharmaceutical company developing a novel oncolytic a |
Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory RetinoblastomaPreclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastomaROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from collaborators at Fundació Sant Joan de Déu that further support evaluation of VCN-01, an oncolytic adenovirus expressin |
Maxim Group Sticks to Its Buy Rating for Synthetic Biologics (SYN)In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Synthetic Biologics (SYN - Research Report), with a price target of $4.00. The company's shares closed yesterday at $1.07.McCarthy covers the Healthcare sector, focusing on stocks such as Adial Pharmaceuticals, Atossa Therapeutics, and Moleculin Biotech. According to TipRanks, McCarthy has an average return of -44.1% and an 8.84% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Synthetic Biologics with a $14.00 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $4. |
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of i |
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patient |
SYN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -29.17% |
| 1-year | -55.65% |
| 3-year | -81.10% |
| 5-year | -99.46% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -28.93% |
| 2020 | -24.44% |
| 2019 | -9.48% |
| 2018 | -96.86% |
Loading social stream, please wait...